Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial
Objective: To assess the incremental cost and cost-effectiveness of continuous and discontinuous regimens of bevacizumab (Avastin) and ranibizumab (Lucentis) for neovascular age-related macular degeneration (nAMD) from a UK National Health Service (NHS) perspective. Design: A within-trial cost-util...
Main Authors: | Dakin, H.A (Author), Wordsworth, S. (Author), Rogers, C.A (Author), Abangma, G. (Author), Raftery, J. (Author), Harding, S.P (Author), Lotery, A.J (Author), Downes, S.M (Author), Chakravarthy, U. (Author), Reeves, B.C (Author) |
---|---|
Format: | Article |
Language: | English |
Published: |
2014-07-29.
|
Subjects: | |
Online Access: | Get fulltext |
Similar Items
-
Comparison of ranibizumab and bevacizumab in neovascular age-related macular degeneration
by: Huseyin Serdarogullari, et al.
Published: (2014-05-01) -
Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?
by: Dimitrios A Karagiannis, et al.
Published: (2009-11-01) -
Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
by: Mohamed A. Hamid, et al.
Published: (2021-04-01) -
Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients
by: Zhe-Li Liu, et al.
Published: (2013-04-01) -
Comparing the Effectiveness of Bevacizumab to Ranibizumab in Patients with Exudative Age-Related Macular Degeneration. The BRAMD Study.
by: A M E Schauwvlieghe, et al.
Published: (2016-01-01)